Stockreport

TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]

TScan Therapeutics, Inc.  (TCRX) 
PDF All treatment-arm patients in the Phase 1 heme program remain relapse-free with no detectable disease, with a median follow-up of 10 months Closed upsized underwritte [Read more]